SEASTAR MEDICAL HOLDING CORP (ICU)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$1.92-5.88%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · ICU
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -67.8% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| 62.4% |
Growth built into the price is above our model estimate.
The price assumes 130.2 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
ICU — capital allocation — Unregistered Sales of Equity Securities
Dated 2026-10-05
Unregistered Sales of Equity Securities. To the extent required by Form 8-K, the disclosures in
Why it matters: SeaStar reported $1.1 million in the first half. Reaching $2 million would support its growth plan.
Supportive ifThe 2026 results report at least $2 million in net QUELIMMUNE product revenue.
Worry ifThe 2026 results report less than $2 million in net QUELIMMUNE product revenue.
Why it matters: The trial tests whether SCD plus standard care lowers death or dialysis dependence. A positive result is key to the adult PMA plan.
Supportive ifThe trial reports a better result for SCD than control on its main measure of death or dialysis dependence at day 90.
Worry ifThe trial reports no better result for SCD than control on its main measure of death or dialysis dependence at day 90.
Why it matters: The codes enable hospital billing for SCD therapy. Their use may ease payment steps for hospitals.
Supportive ifHospital billing records show use of the new SCD ICD-10-PCS codes after October 1, 2026.
Worry ifThe codes do not take effect on October 1, 2026, or hospitals report they cannot use them to bill for SCD therapy.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$273 on $10,000 · ±2.7% | How much price usually moves either way. |
| Bad day | $937 loss on $10,000 · 9.4% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,152 loss on $10,000 · 61.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.